home / stock / ymab / ymab message board
Subject | By | Source | When |
---|---|---|---|
$YMAB: WHAT????? | Invest-in-America | investorshub | 04/02/2023 2:50:17 PM |
there she goes | TrendTrade2016 | investorshub | 03/31/2023 2:34:59 PM |
HERE COMES THE 5 DOLLA BREAK | TrendTrade2016 | investorshub | 03/31/2023 2:28:43 PM |
$YMAB TO 5.34 | TrendTrade2016 | investorshub | 03/31/2023 2:21:26 PM |
YMAB...ANOTHER BIO READY TO FLY | TrendTrade2016 | investorshub | 03/31/2023 2:07:20 PM |
Looks like the train is leaving the station. | weatherfuel | investorshub | 11/02/2022 3:38:44 PM |
Yes it does | INFINITI | investorshub | 10/31/2022 6:48:15 PM |
Looking like a good bounce play setting up. | weatherfuel | investorshub | 10/31/2022 3:52:49 PM |
On the move. | KeepOn | investorshub | 02/13/2022 3:24:00 AM |
TUTES ADDING : including pension plans, Ivy | crudeoil24 | investorshub | 02/11/2022 3:56:18 PM |
HEADING BACK TO $50.00+ > the 52 wk. | crudeoil24 | investorshub | 02/11/2022 3:52:25 PM |
Y-mAbs Announces Completion of Pre-BLA Meeting with FDA | crudeoil24 | investorshub | 02/11/2022 3:39:39 PM |
Y-mAbs Announces Sale of Priority Review Voucher | Phosphene | investorshub | 12/31/2020 1:42:37 PM |
8-K: License agreement with SciClone Pharmaceuticals International. | Phosphene | investorshub | 12/24/2020 2:16:10 AM |
Y-mAbs Announces Pipeline Update | Phosphene | investorshub | 12/17/2020 11:57:56 AM |
SEC Form 4. Director Thomas Gad | Phosphene | investorshub | 12/15/2020 4:01:28 PM |
8K today. Y-mAbs Announces Update on DANYELZA | Phosphene | investorshub | 12/09/2020 11:11:35 PM |
FDA Approves Y-mAbs DANYELZA (naxitamab-gqgk) for the Treatment | Phosphene | investorshub | 12/09/2020 4:16:21 AM |
Y-mAbs to Host Virtual Research & Development Day | Phosphene | investorshub | 12/09/2020 4:15:30 AM |
News, Short Squeeze, Breakout and More Instantly...
Y-mAbs Therapeutics Inc. Company Name:
YMAB Stock Symbol:
NASDAQ Market:
Y-mAbs Therapeutics Inc. Website:
2024-07-05 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic pr...
Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022 Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cash burn of $40-50 millio...